{"id":8816,"date":"2026-01-29T17:41:20","date_gmt":"2026-01-29T17:41:20","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8816"},"modified":"2026-01-29T17:41:20","modified_gmt":"2026-01-29T17:41:20","slug":"serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","title":{"rendered":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment<\/em><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to move forward with regulatory preparations and clinical site activities supporting an upcoming Phase 1b registrational study.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The IND, or Investigational New Drug, clearance marks a critical step in bringing SER-252 closer to patients suffering from advanced Parkinson\u2019s disease, a condition where treatment options remain limited and symptom management becomes increasingly challenging over time. With approval in hand, Serina can now begin patient-focused clinical efforts designed to evaluate the therapy\u2019s safety and potential benefits in real-world clinical settings.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Company leadership described the development as a pivotal moment for the program, emphasizing that regulatory alignment with the FDA helps streamline the path toward eventual approval. The planned clinical program is structured under a 505(b)(2) regulatory pathway, which allows developers to leverage existing data on approved therapies while demonstrating improvements or advantages of a new treatment candidate. This approach can shorten development timelines and reduce overall risk compared with traditional drug approval pathways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In parallel, Serina has begun preparing international clinical infrastructure, including regulatory and site startup activities in Australia, to support what it describes as a global registrational strategy for SER-252.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investor enthusiasm followed the announcement, with shares of the company seeing a strong move higher as markets responded to progress in the pipeline. For patients and clinicians, however, the news signals something more important: continued advancement toward potential new treatment options in a disease area where medical innovation remains urgently needed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As clinical trials begin, the next phase of development will focus on generating data that could ultimately determine whether SER-252 becomes a meaningful addition to Parkinson\u2019s disease therapy in the years ahead.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/nikes-path-back-to-100-why-the-bull-case-is-regaining-momentum\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Nike\u2019s Path Back to $100: Why the Bull Case Is Regaining Momentum<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,359],"tags":[451,421,416,418,901,417],"coauthors":[454],"class_list":["post-8816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-small-cap","tag-fda","tag-growth","tag-movers","tag-news","tag-ser","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T17:41:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light\",\"datePublished\":\"2026-01-29T17:41:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/\"},\"wordCount\":351,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"keywords\":[\"FDA\",\"Growth\",\"Movers\",\"News\",\"SER\",\"Stock Market\"],\"articleSection\":[\"Biotechnology\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/\",\"name\":\"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"datePublished\":\"2026-01-29T17:41:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/29\\\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","og_locale":"en_US","og_type":"article","og_title":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo","og_description":"IND clearance positions SER-252 for clinical progress in advanced Parkinson\u2019s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone this week after receiving clearance from the U.S. Food and Drug Administration (FDA) to proceed with clinical development of SER-252, an investigational therapy aimed at treating advanced Parkinson\u2019s disease. The decision allows the company to [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","og_site_name":"Stoxpo","article_published_time":"2026-01-29T17:41:20+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light","datePublished":"2026-01-29T17:41:20+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/"},"wordCount":351,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","keywords":["FDA","Growth","Movers","News","SER","Stock Market"],"articleSection":["Biotechnology","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/","name":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","datePublished":"2026-01-29T17:41:20+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/29\/serina-therapeutics-advances-parkinsons-program-after-key-fda-green-light\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Serina Therapeutics Advances Parkinson\u2019s Program After Key FDA Green Light"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8816"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816\/revisions"}],"predecessor-version":[{"id":8817,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8816\/revisions\/8817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8816"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}